Industry
Nexstar Pharmaceuticals
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 1(1)
Phase 3(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT00003891Phase 1Completed
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
Role: collaborator
NCT00263315Phase 2Completed
Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
Role: collaborator
NCT00002093Phase 3Completed
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Role: lead
All 3 trials loaded